China smartphone shipments slumped in June on inventory overhang: Jefferies
On Tuesday, BTIG analyst Julian Harrison reaffirmed a Buy rating and a $29.00 price target for Liquidia Technologies (NASDAQ:LQDA), which currently trades at $15.35. According to InvestingPro data, analyst targets range from $13 to $36, with strong consensus leaning toward Buy. Despite a 9.8% decline over the past week, the stock has gained over 32% in the last six months. Harrison highlighted YUTREPIA as the sole approved Dry Powder Inhaler (DPI) treprostinil treatment with sponsored clinical data for both pulmonary hypertension in interstitial lung disease (PH-ILD) and inhaled treprostinil naive pulmonary arterial hypertension (PAH). According to Harrison, the reluctance of United Therapeutics (NASDAQ:UTHR) (Neutral) to study and better inform the use of their Tyvaso DPI in these areas is notable and presents a substantial opportunity for YUTREPIA to cater to the unmet needs within these indications.
Harrison pointed to YUTREPIA’s intrinsic best-in-class features that could support its preferential use. The company maintains a healthy liquidity position with a current ratio of 2.93, indicating strong ability to meet short-term obligations. The update follows a public hearing from the previous Monday, where the North Carolina District Judge overseeing the ’782 lawsuit indicated an intention to issue a decision regarding United Therapeutics’ temporary restraining order (TRO) motion by May 23. The outcome is still pending.
The discussion about a possible bond for United Therapeutics to post was deemed procedural, stemming from previous unsuccessful attempts to enjoin Liquidia. A preliminary injunction (PI) for the ’327 lawsuit was denied last year, casting doubt on the merits of the underlying lawsuit and the likelihood of an injunctive ruling against Liquidia, especially following YUTREPIA’s full FDA approval.
Liquidia Technologies management has scheduled a conference call for 8:30am ET on Wednesday, May 27, to discuss commercial preparations. Harrison noted that BTIG’s estimates are under review after this regulatory milestone. For deeper insights into LQDA’s financial health, valuation metrics, and growth potential, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Liquidia Technologies has been the focus of several analyst evaluations and data presentations. Scotiabank (TSX:BNS) reiterated its Sector Outperform rating for Liquidia, maintaining a $36 price target, following promising results from the ASCENT trial presented at the American Thoracic Society (ATS) conference. The trial highlighted Yutrepia’s potential in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD), with patients showing significant improvement in the 6-minute walk distance test. Needham also maintained a Buy rating with a $25 price target, emphasizing Yutrepia’s potential to improve treatment for pulmonary arterial hypertension (PAH) and PH-ILD, which are currently underserved markets.
Raymond (NSE:RYMD) James expressed optimism by reaffirming a Strong Buy rating and a $29 price target, noting Yutrepia’s favorable safety profile and potential market value. Similarly, BTIG continued its Buy rating with a $29 target, citing new patient data that supports Yutrepia’s therapeutic promise. In contrast, Oppenheimer downgraded Liquidia to Underperform with a $13 target, citing concerns over the market launch of Yutrepia and its differentiation from existing treatments like Tyvaso DPI.
The various analyses reflect a mix of optimism and caution among analysts regarding Liquidia’s market prospects. As Liquidia approaches the May 2025 PDUFA date for Yutrepia, these developments will be closely watched by investors. Each analyst firm has provided insights into the potential challenges and opportunities facing Liquidia, particularly in the competitive landscape of PAH and PH-ILD treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.